Homology Securities Fraud Class Action Ongoing Action: Contact Levi & Korsinsky by May 24, 2022 to discuss your rights – FIXX

New York, New York–(Newsfile Corp. – May 11, 2022) – Levi & Korsinsky, LLP advises investors in Homology Medicines, Inc. (“Homology” or the “Company”) FIXX of a securities class action.

The lawsuit on behalf of the Homology investors was filed in the United States District Court for the Central District of California. The relevant investors purchased or otherwise acquired certain securities of Homology Medicines, Inc. between June 10, 2019 and February 18, 2022. Follow the link below for more information and to be contacted by a member of our team:

Homology Medicines, Inc. Loss Submission Form

or contact Joseph E. Levi, Esq. either by email at [email protected] or by phone at (212) 363-7500. There is no cost or obligation for you.

Can’t see this video? To visit:

Homology Medicines, Inc. NEWS – FIXX NEWS

CASE DETAILS: The filed complaint alleges that the defendants misrepresented and/or concealed that: (i) the company overestimated the efficacy and risk mitigation of its lead product candidate, HMI-102; (ii) as a result, it was unlikely that the Company would be able to market HMI102 in its current form; and (iii) as a result, the Company’s public statements were materially false and misleading at all material times.

WHAT THIS MEANS FOR SHAREHOLDERS: If you have suffered a loss of homology during the period in question, you have until May 24, 2022 ask the court to appoint you as the main plaintiff. Your ability to participate in any collection does not require you to serve as the lead plaintiff.

AT NO CHARGE TO YOU: If you are a class member, you may be entitled to compensation without payment of disbursements or fees. Discuss your rights with our legal team at no cost or obligation.

PROTECT YOUR FINANCIAL INTERESTS: Complete this brief submission form https://www.zlk.com/pslra-1/homology-medicines-inc-loss-submission-form?prid=27124&wire=5 or call 212-363-7500 to discuss the case.

WHY LEVI AND KORSINSKY: Over the past 20 years, the Levi & Korsinsky team has secured hundreds of millions of dollars for aggrieved shareholders and built a track record winning high-stakes cases. Our firm has extensive expertise in representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven consecutive years, Levi & Korsinsky has ranked in the ISS Securities Class Action Services Top 50 Report as one of the top securities litigation firms in the United States.

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/123677

Previous The United States and Western Europe worry about the uncertain end of the war in Ukraine | New Policies
Next Cherry subscription prices frozen for Premier League return